Drug profile · INN
treprostinil sodium
TYVASO
treprostinil sodium (TYVASO) is a prostanoid ip receptor agonist. Associated with United Therapeutics Europe Ltd. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — treprostinil sodium
- US status
- approved
- Class
- —
- Route
- INHALATION
- Patents
- 0
- Programs
- 7
- Data quality
- 0.89
Quick answer
treprostinil sodium (TYVASO) is a prostanoid ip receptor agonist. Associated with United Therapeutics Europe Ltd. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Prostanoid IP receptor agonist
Primary target: Prostacyclin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is treprostinil sodium?
treprostinil sodium (TYVASO) is a prostanoid ip receptor agonist. Associated with United Therapeutics Europe Ltd. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for treprostinil sodium?
TYVASO is a marketed brand name for treprostinil sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of treprostinil sodium?
treprostinil sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.